‘We want to help people add 10-20 years of healthspan’

Optispan’s Matt Kaeberlein on optimizing healthspan, empowering longevity clinics and exploring biological age.

At the end of last year, we brought you the news of the RAPID clinical trial, which is exploring the potential of rapamycin in periodontal disease. The news was made doubly interesting because of the involvement of a longevity company called Optispan, founded by leading aging researcher Dr Matt Kaeberlein. Optispan’s role in the RAPID trial is to monitor biological aging biomarkers, but the company has a broader focus on helping promote longevity and healthspan through “proactive health measures.”

My take on this: Optispan is on a mission to recover the so-called “lost decade” – the years that many people spend in poor health – and ultimately help deliver an increase in healthy lifespan, known as the “longevity dividend.” But how does it plan to do that? We caught up with Kaeberlein to find out.

The fundamental challenge that Optispan is targeting is the healthcare system’s focus on reactive disease care – waiting until people are sick, and then trying to treat their symptoms, with minimal proactive efforts to keep people healthy.

“One of the consequences of that is that ‘sick span’ is increasing in almost every developed country in the world,” says Kaeberlein. “There’s no question that many, many more people are spending more years with one or more chronic diseases, and I don’t think there’s any evidence that healthspan is increasing. I absolutely believe that targeting the biology of aging is a critically important part of optimizing healthspan and longevity.”

Discovering the intricacies of aging biology, Optispan is not a longevity clinic – it dives into exploring biological age and more. Gain more insights straight from Matt Kaeberlein HERE.

Thanks for reading! If you’ve enjoyed this article, it would mean a lot to me if you could subscribe and share it on LinkedIn!